Risk Factors and Multiomics Study of Chronic Kidney Disease Caused by Metabolic Diseases
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- Number of Participants with End Stage Renal Disease
研究概览
简要总结
With the development of China's economy, people's living standard have improved, and the dietary structure have changed. Metabolic diseases, such as hypertension, diabetes, hyperuricemia and obesity have gradually become an important health burden in China. The pathophysiological mechanism of renal injury caused by metabolic diseases has always been a hotspot of research. Currently, it is believed that various mechanisms including the activation of Renin-Angiotensin-Aldosterone System, vascular endothelial dysfunction, oxidative stress and inflammatory process may be involved. Although there are differences in renal pathological manifestations caused by different metabolic diseases, the kidney will eventually present ischemic changes and fibrosis with the progression of the disease. So there must be some common pathogenesis. This study is designed to build a disease cohort of patients with chronic kidney disease caused by metabolic diseases, to identify risk factors leading to disease progression and to explore biomarkers for early diagnosis and treatment of kidney damage.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The diagnosis of metabolic diseases were confirmed;
- •Be able to understand the process of the research;
- •Volunteer for participation and be able to sign the informed consent.
排除标准
- •Age <18 yrs or >80yrs;
- •Patients with primary and secondary glomerular diseases
- •Patients with other comorbidities that could affect the volume or the components of the kidney, such as renal cysts, polycystic kidney disease, medullary sponge kidney, hydronephrosis, renal artery stenosis, renal vein thrombosis and/or renal tumors;
- •Contraindications for MRI examination;
- •Pregnant or lactation patients;
- •Patients with unstable vital signs, failure of other organs or dysphoria.
结局指标
主要结局
Number of Participants with End Stage Renal Disease
时间窗: 3 years
End Stage Renal Disease
Number of Participants with Adverse cardiovascular events
时间窗: 3 years
Adverse cardiovascular events
Number of Participants with all cause death
时间窗: 3 years
All cause death
次要结局
- Number of Participants with eGFR decline(3 years)
- Number of Participants with Complications of CKD(3 years)
- Life quality assessment with short form-36 (SF-36)(3 years)
- Advanced Intelligence Assessment with Mini-Mental State Examination (MMSE)(3 years)
研究者
Limeng Chen
director of the department of nephrology
Peking Union Medical College Hospital